Development of Novel Tumor-Targeting Nanoparticles, 2nd Edition

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: 30 October 2024 | Viewed by 1250

Special Issue Editors


E-Mail Website
Guest Editor
Radiation Oncology Unit, Department of Medical Sciences and Infectious Disease, Fondazione IRCCS, Policlinico San Matteo, Pavia, Italy
Interests: radiotherapy; radiation oncology; GU cancer; lung cancer; radiomics; immunotherapy
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Neurosurgery, University of Tsukuba, Tsukuba, Tennodai, Japan
Interests: neurosurgery
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
International Medical Center, University of Tsukuba Affiliated Hospital, Tsukuba 305-8576, Japan
Interests: cardiovascular immunology; ischemic insult; nanoparticle development; electron microscopy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Based on the success of Volume I of the Special Issue "Development of Novel Tumor-Targeting Nanoparticles" https://www.mdpi.com/journal/pharmaceutics/special_issues/nanoparticles_tumor, we are now launching Volume II. Below is the instruction for it.

Despite the current coronavirus epidemic, cancer remains one of the most pressing problems of humankind, killing about 10 million people in 2020, according to statistics from the World Health Organization. As long as there are cancers that are fatal despite the use of the most modern treatments, there is a need to develop new drugs. Based on numerous published reports, nanoparticles (including liposomes, micelles, etc.) are capable of delivering much larger volumes of active components that stay sequestered in tumor cells for the time required for treatment, and with sufficient active targeting, nanoparticles would have enormous therapeutic potential. Therefore, innovating new tumor-targeting nanoparticles that can change the history of cancer treatment and save the lives of millions of people should be a priority. Therefore, we invite researchers participate in such groundbreaking work to participate in a Special Issue of the journal by submitting their articles for publication in Pharmaceutics.

Dr. Andrea Lancia
Dr. Alexander Zaboronok
Dr. Bryan Mathis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanoparticles
  • nanoliposomes
  • nanomicelles
  • tumor targeting
  • drug delivery system
  • cancer
  • theranostics

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 737 KiB  
Article
A Sensitive Assay for Unbound Docetaxel Using Ultrafiltration plus HPLC-MS and Its Application to a Clinical Study
by David Wang, Natalie Hughes-Medlicott, Lilian Klingler, Yi Wang, Noelyn Hung, Stephen Duffull, Tak Hung, Paul Glue, Albert Qin, Rudolf Kwan, Wing-Kai Chan and Christopher Jackson
Pharmaceutics 2024, 16(5), 602; https://doi.org/10.3390/pharmaceutics16050602 - 29 Apr 2024
Viewed by 524
Abstract
Introduction: Docetaxel, a taxane used in the treatment of solid tumours, exerts pharmacological activity when in its unbound form. We report a sensitive assay to quantify unbound docetaxel after oral administration of docetaxel plus encequidar (oDox+E). Unbound drug quantification is important due to [...] Read more.
Introduction: Docetaxel, a taxane used in the treatment of solid tumours, exerts pharmacological activity when in its unbound form. We report a sensitive assay to quantify unbound docetaxel after oral administration of docetaxel plus encequidar (oDox+E). Unbound drug quantification is important due to its direct correlation with drug-related toxicity and therapeutic efficacy. We improve on the sensitivity of current assay methods and demonstrate the utility of the assay on a novel formulation of oral docetaxel. Methods: Ultrafiltration followed by high-performance liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) was utilized. Long-term stability, precision, accuracy, and recovery experiments were conducted to validate the assay. Additionally, patient samples from a Phase I dose-escalation pharmacokinetic study were analyzed using the developed assay. Results: The assay method exhibited long-term stability with an observed change between 0.8 and 6.9% after 131 days of storage at −60 °C. Precision and accuracy quality controls met the FDA acceptance criteria. An average recovery of 88% was obtained. Patient sample analysis demonstrated successful implementation of the assay. Conclusion: A validated sensitive assay was developed with an LLOQ of 0.084 ng/mL using 485 µL of human plasma. The sensitivity of the assay allowed quantification of unbound docetaxel concentrations in an early-phase oDox+E clinical study to compare it against IV docetaxel using pharmacokinetic modelling. Successful development of oDox+E represents an opportunity to replace the current IV docetaxel regimen with an oral regimen with lower cost, decreased side effects, and improve patient quality of life and experience. Full article
(This article belongs to the Special Issue Development of Novel Tumor-Targeting Nanoparticles, 2nd Edition)
Show Figures

Figure 1

Back to TopTop